Literature DB >> 23524643

Multivalent Interactions: Synthesis and Evaluation of Melanotropin Multimers - Tools for Melanoma Targeting.

Nabila Brabez1, Kara Saunders, Kevin L Nguyen, Thanuja B M Jayasundera, Craig Weber, Ronald M Lynch, Gerard Chassaing, Solange Lavielle, Victor J Hruby.   

Abstract

In order to develop agents for early detection and selective treatment of melanomas, high affinity and high specificity molecular tools are required. Enhanced specificity may be obtained by simultaneously binding to multiple cell surface targets via the use of multimeric analogs of naturally occurring ligands. Trimers targeting overexpressed melanocortin receptors have been found to be potential candidates for this purpose. In the present letter, we describe the synthesis and study of multimers based on a dendrimer-like scaffold. The binding affinity and activity results revealed that dendrimers promote multivalent interactions via statistical and/or cooperative effects on binding. Moreover, viability studies showed no significant toxicity at micromolar concentrations, which will allow these molecular complexes to be used in vivo. Finally, imaging studies showed effective internalization for all the molecules confirming their potential as delivery agents.

Entities:  

Keywords:  Multivalent interactions; cancer; delivery; dendrimers; melanoma; multimers; peptides; targeted therapy

Year:  2012        PMID: 23524643      PMCID: PMC3601667          DOI: 10.1021/ml300312b

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  24 in total

Review 1.  Hitting multiple targets with multimeric ligands.

Authors:  Heather L Handl; Josef Vagner; Haiyong Han; Eugene Mash; Victor J Hruby; Robert J Gillies
Journal:  Expert Opin Ther Targets       Date:  2004-12       Impact factor: 6.902

2.  Detection of low-affinity adhesion ligands by linking recombinant cell adhesion molecules in uniform orientation to a fluorescently labelled dextran molecule by means of hexahistidine tagging: the case of multimeric CD40.

Authors:  G Vassiliou; K Jakobsen; C R Parish
Journal:  J Immunol Methods       Date:  1998-06-01       Impact factor: 2.303

3.  Design, synthesis, and biological studies of efficient multivalent melanotropin ligands: tools toward melanoma diagnosis and treatment.

Authors:  Nabila Brabez; Ronald M Lynch; Liping Xu; Robert J Gillies; Gerard Chassaing; Solange Lavielle; Victor J Hruby
Journal:  J Med Chem       Date:  2011-10-03       Impact factor: 7.446

Review 4.  Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression.

Authors:  Shuyu Li; Shuguang Huang; Sheng-Bin Peng
Journal:  Int J Oncol       Date:  2005-11       Impact factor: 5.650

5.  "Peptabody": a new type of high avidity binding protein.

Authors:  A V Terskikh; J M Le Doussal; R Crameri; I Fisch; J P Mach; A V Kajava
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

Review 6.  Lanthanide-based luminescent assays for ligand-receptor interactions.

Authors:  Heather L Handl; Robert J Gillies
Journal:  Life Sci       Date:  2005-02-19       Impact factor: 5.037

Review 7.  Dendrimer-based nanoparticles for cancer therapy.

Authors:  James R Baker
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

8.  Lanthanide-based time-resolved fluorescence of in cyto ligand-receptor interactions.

Authors:  Heather L Handl; Josef Vagner; Henry I Yamamura; Victor J Hruby; Robert J Gillies
Journal:  Anal Biochem       Date:  2004-07-15       Impact factor: 3.365

Review 9.  Therapeutic and diagnostic applications of dendrimers for cancer treatment.

Authors:  Jesse B Wolinsky; Mark W Grinstaff
Journal:  Adv Drug Deliv Rev       Date:  2008-03-04       Impact factor: 15.470

Review 10.  Immunohistochemistry in melanocytic proliferative lesions.

Authors:  N J W de Wit; G N P van Muijen; D J Ruiter
Journal:  Histopathology       Date:  2004-06       Impact factor: 5.087

View more
  6 in total

Review 1.  Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.

Authors:  Mark D Ericson; Cody J Lensing; Katlyn A Fleming; Katherine N Schlasner; Skye R Doering; Carrie Haskell-Luevano
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-03-29       Impact factor: 5.187

2.  Synthesis and bioactivity of MSH4 oligomers prepared by an A2 + B2 strategy.

Authors:  Dilani Chathurika Dehigaspitiya; Suryakiran Navath; Craig S Weber; Ronald M Lynch; Eugene A Mash
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

3.  Developing a Biased Unmatched Bivalent Ligand (BUmBL) Design Strategy to Target the GPCR Homodimer Allosteric Signaling (cAMP over β-Arrestin 2 Recruitment) Within the Melanocortin Receptors.

Authors:  Cody J Lensing; Katie T Freeman; Sathya M Schnell; Robert C Speth; Adam T Zarth; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2018-05-09       Impact factor: 7.446

4.  Trigonal scaffolds for multivalent targeting of melanocortin receptors.

Authors:  N G R Dayan Elshan; Thanuja Jayasundera; Bobbi L Anglin; Craig S Weber; Ronald M Lynch; Eugene A Mash
Journal:  Org Biomol Chem       Date:  2015-02-14       Impact factor: 3.876

5.  Development of Radiogallium-Labeled Peptides for Platelet-Derived Growth Factor Receptor β (PDGFRβ) Imaging: Influence of Different Linkers.

Authors:  Nurmaya Effendi; Kenji Mishiro; Kazuhiro Shiba; Seigo Kinuya; Kazuma Ogawa
Journal:  Molecules       Date:  2020-12-23       Impact factor: 4.411

6.  (64)Cu-labeled LyP-1-dendrimer for PET-CT imaging of atherosclerotic plaque.

Authors:  Jai Woong Seo; Hyounggee Baek; Lisa M Mahakian; Jiro Kusunose; Juliana Hamzah; Erkki Ruoslahti; Katherine W Ferrara
Journal:  Bioconjug Chem       Date:  2014-01-31       Impact factor: 4.774

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.